TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter – Hagens Berman

Telix Pharmaceuticals is facing a securities class action lawsuit after revealing an SEC investigation into its prostate cancer therapeutic candidates and receiving a Complete Response Letter from the FDA for its Zircaix drug, which caused significant stock price decline.

Insights
TLX   negative

Company received an SEC subpoena, FDA Complete Response Letter, and is now facing a securities class action lawsuit alleging misleading statements about drug development progress and manufacturing capabilities, which led to substantial stock price drops